Assessing the Impact of Racist Incidents on the community in Plymouth.

This report details the findings of research, funded by the University of Plymouth, to evaluate and assess the impact of racist incidents on the community in Plymouth. It has been acknowledged by Plymouth and Devon Racial Equality Council (PDREC) that since the beginning of the Covid-19 pandemic in March 2020, they have recorded an increase in racist incidents within Plymouth, particularly in the postcode PL1 area. This research aims to provide a resource for PDREC, the local authority, agencies, and communities to address racist incidents and to provide a platform to help build resilience towards racism. The research was a collaborative project between researchers from the University of Plymouth and employees of PDREC. Research team members included Dr Chris Pac-Soo of the University of Plymouth School of Society and Culture, Emma Taylor of the University of Plymouth School of Society and Culture, as well as Lavinia Porfir, community engagement worker, of Plymouth and Devon Racial Equality Council. Objective

Vascular surgery-related organ injury and protective strategies: update and future prospects

Whilst there has been a reduction in the prevalence of peripheral vascular disease worldwide, a significant proportion of the world's growing population is still affected by disease of the aorta, carotid, iliac and lower limb arteries. These if left untreated can result in severe morbidity and mortality. However vascular surgery, the main definitive treatment for such conditions, is associated with subsequent injury to vital organs including the kidneys, heart, brain, intestines and lungs, with a consequent increase in both morbidity and mortality. The current thinking is that the underlying mechanism of injury is direct organ ischaemia and ischaemia induced formation of free radicals, cytokine release and mitochondrial failure. Various methods to alleviate such injuries have been investigated including pre- and postconditioning strategies, pharmacological therapies including volatile anaesthetic and alpha2 adrenoceptor agonist drugs and more recently remote conditioning strategies. Although these interventions have demonstrated some reduction in the biomarkers for organ injury, attempts to translate these benefits into clinical practice have not been successful in terms of morbidity, mortality or length of hospital stay. For this reason, further research is needed in this area to facilitate the translation of the potential interventional benefits from bench to bedside

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterResearch in context

Summary: Background: SARS-CoV-2 booster vaccination should ideally enhance protection against variants and minimise immune imprinting. This Phase I trial evaluated two vaccines targeting SARS-CoV-2 beta-variant receptor-binding domain (RBD): a recombinant dimeric RBD-human IgG1 Fc-fusion protein, and an mRNA encoding a membrane-anchored RBD. Methods: 76 healthy adults aged 18–64 y, previously triple vaccinated with licensed SARS-CoV-2 vaccines, were randomised to receive a 4th dose of either an adjuvanted (MF59®, CSL Seqirus) protein vaccine (5, 15 or 45 μg, N = 32), mRNA vaccine (10, 20, or 50 μg, N = 32), or placebo (saline, N = 12) at least 90 days after a 3rd boost vaccination or SARS-CoV-2 infection. Bleeds occurred on days 1 (prior to vaccination), 8, and 29. ClinicalTrials.gov NCT05272605. Findings: No vaccine-related serious or medically-attended adverse events occurred. The protein vaccine reactogenicity was mild, whereas the mRNA vaccine was moderately reactogenic at higher dose levels. Best anti-RBD antibody responses resulted from the higher doses of each vaccine. A similar pattern was seen with live virus neutralisation and surrogate, and pseudovirus neutralisation assays. Breadth of immune response was demonstrated against BA.5 and more recent omicron subvariants (XBB, XBB.1.5 and BQ.1.1). Binding antibody titres for both vaccines were comparable to those of a licensed bivalent mRNA vaccine. Both vaccines enhanced CD4+ and CD8+ T cell activation. Interpretation: There were no safety concerns and the reactogenicity profile was mild and similar to licensed SARS-CoV-2 vaccines. Both vaccines showed strong immune boosting against beta, ancestral and omicron strains. Funding: Australian Government Medical Research Future Fund, and philanthropies Jack Ma Foundation and IFM investors

LORIS (Longitudinal Online Research and Imaging System)

<h2>What's Changed</h2> <ul> <li>[media] React Warning on Upload Tab by @skarya22 in https://github.com/aces/Loris/pull/8721</li> <li>[issue_tracker] Do not display inactive users in issue form by @charlottesce in https://github.com/aces/Loris/pull/8841</li> <li>[LINST] skip metadatafields for surveys by @zaliqarosli in https://github.com/aces/Loris/pull/8961</li> <li>[dictionary] Fixes for correct displaying "Data Type" column for the enumeration type in the "Data Dictionary (Beta)" table by @yagurdmitriy in https://github.com/aces/Loris/pull/8976</li> <li>[tools] Fix efficiency of fix_candidate_age script by @CamilleBeau in https://github.com/aces/Loris/pull/8992</li> <li>[media] fixes issue when media module try to instantiate a non existing instrument. by @racostas in https://github.com/aces/Loris/pull/8903</li> <li>[instrument_list] Fix deprecation warning by @driusan in https://github.com/aces/Loris/pull/8867</li> <li>[LINST] fix survey and date issues by @ridz1208 in https://github.com/aces/Loris/pull/8858</li> <li>[JSX] Modal Width Prop by @skarya22 in https://github.com/aces/Loris/pull/8893</li> <li>[libraries] Get examiner sites by UserID by @CamilleBeau in https://github.com/aces/Loris/pull/8994</li> <li>[genomic_browser] Download button not showing up in the Files tab by @ridz1208 in https://github.com/aces/Loris/pull/8480</li> <li>[issue_tracker - raisinbread/tools] Fix issue tracker history wrong module ID by @zaliqarosli in https://github.com/aces/Loris/pull/8677</li> <li>[Issue Tracker] Issue Change Notifications by @skarya22 in https://github.com/aces/Loris/pull/8885</li> <li>[behavioural_qc] fixes visitLevel feedback not showing up. by @racostas in https://github.com/aces/Loris/pull/8900</li> <li>[battery_manager] Update Test Plan by @skarya22 in https://github.com/aces/Loris/pull/8782</li> </ul> <h2>New Contributors</h2> <ul> <li>@yagurdmitriy made their first contribution in https://github.com/aces/Loris/pull/8976</li> </ul> <p><strong>Full Changelog</strong>: https://github.com/aces/Loris/compare/v25.0.1...v25.0.2</p>If you use this software, please cite it using these metadata